Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Targets ALS In Expansion Of Cytokinetics Alliance

Executive Summary

Astellas and Cytokinetics are expanding their existing alliance to investigate two candidates against amyotrophic lateral sclerosis, as the Japanese firm looks to build its strategic interests in muscle disease.

Advertisement

Related Content

Finance Watch: $50m Doubles Magenta's Funding To Improve Stem Cell Transplants
Cytokinetics Seeks ALS Success By Focusing On Lung Function
Big US Step For Mitsubishi Tanabe As Edaravone Filed For ALS
Astellas Jump-Starts Ophthalmology Ambitions With Ocata Buy
Cytokinetics gets up to $675m in expanded Astellas deal
Cytokinetics plunges as tirasemtiv fails to BENEFIT-ALS

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097004

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel